NCE-1 Intelligence & Market Opportunity

Azstarys

Serdexmethylphenidate And dexmethylphenidate

CNS stimulant

Oral Capsule

Approval Date

03-Feb-21

NCE-1 Date

03-Feb-25

NCE Date

03-Feb-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

1.5304

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

132

2028

168

2029

205

2030

240

2031

276

2032

312

Molecule profile

Details & specifications

Molecule

Serdexmethylphenidate And dexmethylphenidate

Innovator

COMMAVE SUB, LLC

Dosage Form

Oral Capsule

Strength

EQ 7.8 mg base, EQ 10.4 mg base, EQ 5.2 mg base

Therapeutic Category

CNS stimulant

Usage

To treat attention deficit hyperactivity disorder

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.